Evidence map›Paper›PMID 22868499›Full record

ArticleInfection and immunity2012

The Asd(+)-DadB(+) dual-plasmid system offers a novel means to deliver multiple protective antigens by a recombinant attenuated Salmonella vaccine.

Wei Xin, Soo-Young Wanda, Xiangmin Zhang, Javier Santander, Giorgio Scarpellini, Karen Ellis, Praveen Alamuri, Roy Curtiss

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. AttenuatedVirulence · 2019
    Article
  6. Two NovelFrontiers in cellular and infection microbiology · 2017
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Development ofVaccines · 2014
    Article
  12. Article
  13. Serotype-independent pneumococcal vaccines.Cellular and molecular life sciences : CMLS · 2013
    Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Wei XinCenter for Infectious Diseases and Vaccinology, The Biodesign Institute, Arizona State University, Tempe, Arizona, USA.
Soo-Young Wanda
Xiangmin Zhang
Javier Santander
Giorgio Scarpellini
Karen Ellis
Praveen Alamuri
Roy Curtiss
Arizona State University · US

Funding

Recombinant Attenuated Salmonella Vaccines for HumansR01AI056289 · NIAID · WASHINGTON UNIVERSITY · PI CLARK-CURTISS, JOSEPHINE E, CURTISS III, ROY · 2003 to 2018
$5.8M
Salmonella Vaccines Against Bacterial EnteropathogensR01AI060557 · NIAID · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI CURTISS III, ROY · 2010 to 2014
$2.2M
NIAID NIH HHS R01 AI056289NIAID NIH HHS R01 AI060557
6 · The paper itself

Abstract

We developed means to deliver multiple heterologous antigens on dual plasmids with non-antibiotic-resistance markers in a single recombinant attenuated vaccine strain of Salmonella enterica serotype Typhimurium. The first component of this delivery system is a strain of S. Typhimurium carrying genomic deletions in alr, dadB, and asd, resulting in obligate requirements for diaminopimelic acid (DAP) and d-alanine for growth. The second component is the Asd(+)-DadB(+) plasmid pair carrying wild-type copies of asdA and dadB, respectively, to complement the mutations. To evaluate the protection efficacy of the dual-plasmid vaccine, S. Typhimurium strain χ9760 (a strain with multiple attenuating mutations: Δasd Δalr ΔdadB ΔrecF) was transformed with Asd(+) and DadB(+) plasmids specifying pneumococcal antigens PspA and PspC, respectively. Both plasmids were stable in χ9760 for 50 generations when grown in nonselective medium. This was significantly (P < 0.05) greater than the stability seen in its recF(+) counterpart χ9590 and could be attributed to reduced interplasmid recombination in χ9760. Oral immunization of BALB/c mice with 1 × 10(9) CFU of χ9760 (carrying Asd(+)-PspA and DadB(+)-PspC plasmids) elicited a dominant Th1-type serum IgG response against both antigens and protected mice against intraperitoneal challenge with 200 50% lethal doses (LD(50)s) of virulent Streptococcus pneumoniae strain WU2 or intravenous challenge with 100 LD(50)s of virulent S. pneumoniae strain L81905 or intranasal challenge with a lethal dose of S. pneumoniae A66.1 in a pneumonia model. Protection offered by χ9760 was superior to that offered by the mixture of two strains, χ9828 (Asd(+)-PspA) and χ11026 (DadB(+)-PspC). This novel dual-plasmid system marks a remarkable improvement in the development of live bacterial vaccines.

Indexed as

PlasmidsAnimalsAntibodies, BacterialAntigens, BacterialBacterial ProteinsFemaleImmunoglobulin AImmunoglobulin GMiceMice, Inbred BALB CPneumonia, PneumococcalRecombinant ProteinsSalmonella Infections, AnimalSalmonella typhimuriumSalmonella VaccinesVaccines, AttenuatedAntibodies, BacterialAntigens, BacterialBacterial ProteinsImmunoglobulin AImmunoglobulin GRecombinant ProteinsSalmonella VaccinesVaccines, AttenuatedVaccines, Synthetic

Identifiers

PMID22868499
PMCPMC3457550
OpenAlexW2169483956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.